Other languages Adagene Inc.

Equities

ADAG

US0053291078

Delayed Nasdaq Other stock markets 01:25:40 2024-05-02 pm EDT			5-day change	1st Jan Change
2.41 ^USD	+3.43%		+2.55%	+24.77%

Mar. 29	Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 29	Adagene Inc. Announces Board Changes	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29
Adagene Inc. Announces Board Changes	Mar. 29
Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board	Mar. 07
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Feb. 09
Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination	Feb. 09
Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody	Feb. 09
Adagene Reports Positive Data on Colorectal Cancer Treatment Combination	Jan. 17
Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium	Jan. 16
Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126	Nov. 03
Adagene Inc. Announces Resignation of Fangyong Du as Chief Technology Officer	23-09-29
Adagene Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second Safebody® Novel Masked Antibody-Drug Conjugate	23-05-04
Adagene Inc. Announces Board Changes	23-04-28
Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28
Adagene Inc. Appoints Aurélien Marabelle to Scientific and Strategic Advisory Board	23-03-05
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-Ctla-4 Safebody® Adg126 Up to 10 Mg/Kg with Repeat Cycles in Combination with Anti-Pd-1 Therapy from Dose Escalation Portion of Phase 1B/2 Trial	23-01-09
Adagene, Roche Partner to Assess ADG126 Combined With Atezolizumab, Bevacizumab in Advanced Liver Cancer Trial	22-12-16
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbodyÂ® ADG126 in Combination with Rocheâ€™s Standard-of-Care for First-Line Advanced Liver Cancer	22-12-16
Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee	22-11-21
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors	22-11-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Adagene Inc.

Equities

ADAG

US0053291078

Other languages

Filters